- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03606070
Multiparametric PET-MRI Integration for a New Approach to Tumor Heterogeneity in Non-Small Cell Lung Cancer (NSCLC): Pilot Study (IMAHTEP)
January 2, 2019 updated by: Gustave Roussy, Cancer Campus, Grand Paris
To estimate the intra and inter-operator reproducibility of multiparametric regional PET-MRI mapping in locally advanced and trace mestastatic non-small cell lung cancer (NSCLC).
Study Overview
Study Type
Interventional
Enrollment (Anticipated)
20
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Caroline CARAMELLA, MD
- Phone Number: +33 0142114211
- Email: caroline.caramella@gustaveroussy.fr
Study Locations
-
-
Val De Marne
-
Villejuif, Val De Marne, France, 94805
- Recruiting
- Gustave Roussy
-
Contact:
- Caroline CARAMELLA, MD
- Phone Number: 0142114211
- Email: caroline.caramella@gustaveroussy.fr
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Locally advanced NSCLC (stages IIB, IIIA or IIIB of the TNM classification 7th edition) or trace metastatic stage IV (</=5 mestastasis, </= 3 organ reached)
- Exclusive therapeutic management by concomitant radio-chemotherapy administered in accordance with international recommendations (dual therapy with platinum salts)
- Signed consent
- Patients affiliated with the social security scheme or beneficiary of a similar scheme.
Exclusion Criteria:
- Minor
- Pregnant / lactating woman
- Person deprived of liberty by judicial or administrative decision, adults who are the subject of a legal protection measure or unable to express their consent
- Previous cancer in the 2 years prior to registration
- Previousradiotherapy / thoracic surgery
- Patients under experimental treatment or for whom the administration of an experimental treatment is planned
- Claustrophobic patients
- Severe Renal Insufficiency (Clearance MDRD Cockroft <30ml / min)
- Uncontrolled diabetes, hyperglycemia> 1.8g / L
- Patient with metallic implants not compatible with MRI or any immovable implanted electronic medical device (eg pacemaker, neurostimulator, cochlear implants, etc.)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: DIAGNOSTIC
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
OTHER: Patients with NSCLC
Characterization of tumor heterogeneity by multiparametric regional mapping PET-MRI. Patients will realize:
|
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Measurement of intra and inter-operator reproducibility of multiparametric regional PET-MRI mapping performed before and under treatment.
Time Frame: Up to 24 months
|
Up to 24 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
November 25, 2017
Primary Completion (ANTICIPATED)
May 1, 2019
Study Completion (ANTICIPATED)
November 1, 2020
Study Registration Dates
First Submitted
July 20, 2018
First Submitted That Met QC Criteria
July 20, 2018
First Posted (ACTUAL)
July 30, 2018
Study Record Updates
Last Update Posted (ACTUAL)
January 4, 2019
Last Update Submitted That Met QC Criteria
January 2, 2019
Last Verified
January 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2016-A02074-47
- 2016/2499 (OTHER: CSET number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on NSCLC
-
Shanghai Henlius BiotechCompleted
-
The Netherlands Cancer InstituteEnrolling by invitation
-
Centre Oscar LambretUniversity Hospital, LilleTerminated
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdCompleted
-
Bio-Thera SolutionsCompleted
-
Jiangsu Province Nanjing Brain HospitalRecruiting
-
TYK Medicines, IncRecruiting
-
Radboud University Medical CenterPfizer; ImaginAb, Inc.; University Hospital TuebingenNot yet recruitingNSCLCGermany, Netherlands
-
Beta Pharma, Inc.Completed
Clinical Trials on PET-MRI
-
Cambridge University Hospitals NHS Foundation TrustRecruitingBreast CancerUnited Kingdom
-
Jeffrey A. Lieberman, MDTerminated
-
New York State Psychiatric InstituteNational Institute of Mental Health (NIMH)TerminatedSchizophreniaUnited States
-
Maastricht University Medical CenterCompletedOvarian NeoplasmsNetherlands
-
Università Vita-Salute San RaffaeleIRCCS San Raffaele; Associazione Italiana per la Ricerca sul CancroNot yet recruitingBreast Cancer Female | Lobular Breast Carcinoma | Luminal A Breast Cancer | PET/MRI | Axillary Lymphadenopathy
-
University of EdinburghActive, not recruiting
-
NYU Langone HealthDendreonTerminatedProstate CancerUnited States
-
Washington University School of MedicineNational Cancer Institute (NCI)Terminated
-
Massachusetts General HospitalRecruiting
-
Xuzhou Medical UniversityUnknownProstate Cancer